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Abstract
Background: It is unclear whether health related quality of life (HRQL) may have a predictive value for mortality in
idiopathic pulmonary fibrosis (IPF).
We investigated the relationship between HRQL assessed using the St. George’s Respiratory Questionnaire (SGRQ)
and survival time in patients with IPF, and tried to determine a clinical meaningful cut off value to predict poorer
survival rates.
Methods: We retrospectively analyzed consecutive patients with IPF who underwent an initial evaluation from May
2007 to December 2012. The diagnosis of IPF was made according to the 2011 international consensus guidelines.
We used Cox proportional hazard models to identify independent predictors for mortality rate in patients with IPF.
Results: We examined 182 eligible cases, average age was 66 years old, and 86% were male. Mean levels of percent
predicted FVC, DLco, six-minute-walk test distance, and the SGRQ total score were around 80%, 58%, 580 m, and 34
points. On multivariate analysis, the SGRQ total score (hazard ratio [HR], 1.012; 95% confidence interval [CI] 1.001–1.023;
P = .029) and percent predicted FVC (HR, 0.957; 95% CI 0.944–0.971, P < .001) were independent predictors for mortality
rate. Moreover, a score higher than 30 points in the SGRQ total score showed higher mortality rate (HR, 2.047; 95% CI,
1.329–3.153; P = .001).
Conclusions: The SGRQ total score was one of independent prognostic factors in patients with IPF. Total scores
higher than 30 points were associated with higher mortality rates.
Trial registration: This study was retrospective, observational study, so it is not applicable.
Keywords: Health related QoL, Idiopathic pulmonary fibrosis, Prognostic factors, The St. George’s Respiratory
Questionnaire
Background
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease
characterized by chronic, progressive fibrosing intersti-
tial pneumonia of unknown etiology [1]. As the disease
condition progresses, dyspnoea on exertion becomes
severe and health-related quality of life (HRQL) seriously
deteriorates [2].
HRQL is a subjective and multidimensional appraisal
that focuses on the impact of illness and treatment on
physical, emotional, and social well-being [3]. HRQL tools
can thus capture various information that physiologic or
radiologic measures cannot. Therefore, it has been consid-
ered to be one of the most important endpoints in
pharmacological trials and rehabilitation for IPF [4, 5].
The St. George’s Respiratory Questionnaire (SGRQ) is
the most frequently used tool to measure HRQL. It was
developed as a standardized, self-administered, disease-
specific health status evaluation scale for patients with
chronic obstructive disease [6]. The questionnaire con-
sists of 50 items with 76 weighted responses that pro-
duce scores in three domains and one total score. The
domains are symptoms (breathlessness, cough, and
wheeze), activities (that are limited by the symptoms),
and impacts (social and psychologic effect of the respira-
tory diseases). The score for each domain is calculated
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from 0 to 100, with higher scores corresponding to
worse HRQL.
In patients with COPD, the SGRQ was shown to be a
significant predictor of mortality [7, 8]. However, in
patients with IPF, the relationship between HRQL
assessed using the SGRQ and mortality has not fully
been studied.
The aim of the present study was to investigate
whether the SGRQ has a predictive value for mortality
in IPF, including various dimensional clinical factors pre-
viously reported as prognostic factors, namely MMRC
[9], % predicted FVC, % predicted DLco [1, 10–15],
6MWD, desaturation during 6MWT [13, 16–18], and
BMI [19]. We also sought a clinically meaningful cut off
value to predict poorer mortality rate.
Methods
Study subjects
Two-hundred and five consecutive patients with IPF,
who underwent systemic initial evaluation from May
2007 to December 2012 at a center for respiratory dis-
eases (Aichi, Japan), were identified from their medical
records. The diagnosis of IPF was made according to the
2011 international consensus guidelines, and since 2011
the accuracy of the diagnosis has been confirmed by
multidisciplinary discussion (MDD); however, some of
the patients who initially presented before 2010 had
been diagnosed based on different guidelines. The diag-
nosis for these patients was therefore confirmed according
to the 2011 guidelines and MDD before May 2015 [1]. A
thoracic radiologist with 27 years of experience re-read
the chest high-resolution CT (HRCT) that had been
obtained at the initial evaluation. This thoracic radiolo-
gist was blind to the clinical course and examination
data for each patient.
Patients were excluded from the present study if there
was clinical evidence of other known conditions, such as
connective tissue disease, left heart failure, an occupa-
tional or environmental exposure that may result in
interstitial lung disease, or a history of ingestion of an
agent known to cause interstitial lung disease. Moreover,
patients who had been prescribed medication for IPF (i.e.
anti-fibrotic drug, corticosteroid, immunosuppressant), or
who had undergone long-term oxygen therapy before
initial evaluation at a center for respiratory diseases
(Aichi, Japan) were also excluded. Finally, we examined
182 patients with IPF who were newly diagnosed. Of
them, 55 patients who were in a clinical trial were
enrolled. The present study was approved by a local insti-
tutional review board (IRB No. 509).
Data collection
Clinical data were retrospectively collected from a medical
chart review. The eligible patients had undergone all of
the tests and assessments that were physical examination
and assessment of physiological function, dyspnoea (modi-
fied Medical Research Council (MMRC) scale and
Baseline Dyspnoea Index (BDI) score), exercise capacity
(6-minute-walk test (6MWT) and desaturation during
6MWT), and HRQL, which was assessed using the
SGRQ [6] at the initial evaluation. The Japanese version
of the SGRQ has been previously validated [20].
All patients completed pulmonary function tests
(PFTs) by spirometry (CHESTAC-55 V; Chest, Tokyo,
Japan), according to the ATS/ERS criteria [21]. Diffusion
capacity for carbon monoxide (DLco) was also measured
(CHESTAC-55 V). The values for forced vital capacity
(FVC), forced expiratory volume in 1 second (FEV1),
and DLco were measured according to the American
Thoracic Society/European Respiratory Society recom-
mendation [22]. The 6MWT was performed according
to the ATS/ERS criteria [23]. The duration from initial
evaluation to the last attendance or death was recorded.
We analyzed censored cases by calling them to confirm
their life-or-death status.
Statistical analysis
We performed all analyses by using SPSS (version 22;
Chicago, IL, USA). Clinical variables were used as con-
tinuous variables, except that the categorical variables of
gender, smoking status, and a history of surgical lung
biopsy were coded as one or zero for the analyses. Con-
tinuous variables were presented as mean ± standard
deviation unless otherwise stated. Categorical variables
were reported as counts and percentages. The survival
time was calculated with the life table method. We per-
formed univariate and multivariate Cox proportional
hazards analyses to investigate the relationships between
clinical variables and mortality rate with adjustment for
age and gender. Results of Cox proportional hazards
analyses were presented in terms of estimated hazard
ratios (HRs) with corresponding 95% confidence inter-
vals (CI); p values of less than 0.05 were considered to
be statistically significant. In order to select final prog-
nostic predictors in multivariate analysis, all candidate
predictors for which the p-value was < 0.1 on univariate
analysis were included in a forward selection method,
with a p-value of 0.05 used for final entry or removal.
To avoid multicollinearity, some of the highly correlated
variables were excluded on multivariate analysis if they
had Pearson’s correlation coefficients higher than 0.7.
We performed a receiver operating characteristic (ROC)
curve analysis to find an optimized cutoff value for 3-year
survival prediction. Survival curves were estimated using
the Kaplan–Meier method, and compared using the
log-rank test across the higher and lower groups of the
SGRQ total score.
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Results
Patient characteristics
The characteristics of the study population are shown in
Table 1. Average age was 65.6 years old, and 85.2% of
the patients were male. Surgical lung biopsy was per-
formed to diagnose IPF in 97 patients (53.3%). Median
follow-up time was 36.1 months (interquartile range,
19.3 to 48.6 months), 12 cases were lost to follow-up,
and 94 patients (51.6%) died within the follow-up times.
MST was 48.3 months (95% CI, 43.5 to 53.1 months).
Baseline levels of clinical indices
Table 1 shows all variables we collected in the present
study: mean levels of PaO2, the pulmonary function test,
exercise capacity, dyspnoea scale and HRQL score. Mean
percent predicted FVC was 79.7%, mean percent predicted
DLco was 58.2%. Mean score on the SGRQ total domain
was 34.5 points and its distribution is shown in Fig. 1. The
relationship between SGRQ and baseline physiological
measures is shown in Additional file 1: Table S1. Comor-
bidities, especially diabetes and orthopedic disease, were
related to SGRQ total score. However, they did not have
predictive value for mortality with adjustment for age and
gender (HR, 1.449; 95% CI 0.901–2.332, P = 0.13, HR,
0.748; 95% CI 0.325–1.720, P = 0.49, respectively) (Add-
itional file 1: Table S2).
Correlation between baseline levels of clinical indices and
mortality
On univariate analysis, all domain scores of the SGRQ
showed significant predictive value for mortality (Table 2).
Moreover, symptom, impact, and total domain showed sig-
nificant predictive value for mortality with adjustment for
age, gender, and %FVC model (Additional file 1: Table S3).
Table 1 Baseline characteristics of study populationa (N = 182)
Characteristic
Age, y 65.6 ± 8.0
Male gender, N (%) 155 (85.2)
BMI, kg/m2 24.0 ± 3.4
Ever smoking, N (%) 147 (81.9)
Surgical Lung Biopsy, N (%) 97 (53.3)
Arterial blood gas analysis
PaO2, mmHg 82.0 ± 11.6
Pulmonary function
FVC, % predicted 79.7 ± 19.1
FEV1 / FVC 85.2 ± 7.5
DLco, % predicted (N = 179) 58.2 ± 20.1
Dyspnoea index
MMRC (0/1/2/3/4) 51 / 74 / 41 / 15 / 1
BDI (N = 180) 8.9 ± 2.4
6MWT (N = 181)
6MWD, m 580 ± 136
SpO2 nadir, % 82.8 ± 9.1
SGRQ score
Symptom 44.2 ± 22.6
Activity 40.0 ± 26.1
Impact 27.7 ± 19.8
Total 34.5 ± 20.2
BMI body mass index, FVC % predicted percent predicted forced vital capacity;
FEV1 forced expiratory volume in the first second, DLCO % predicted percent
predicted diffusion capacity for carbon monoxide, PaO2 partial pressure for
oxygen, 6MWD 6-min walk distance, SpO2 oxygen saturation by pulse oximetry
aPlus–minus values are means ± SD
Fig. 1 The distribution histogram for SGRQ
Table 2 Univariate Cox proportional-hazard analysis
Variables Adjusted HRs (95% CI)a p value
Age, y 1.005 (0.979–1.031) 0.72
Male gender 0.725 (0.394–1.334) 0.30
BMI, kg/m2 0.882 (0.826–0.942) <0.001
PaO2, mmHg 0.978 (0.961–0.996) 0.014
FVC, % predicted 0.954 (0.941–0.967) <0.001
DLco, % predicted 0.976 (0.964–0.989) <0.001
MMRC 1.413 (1.14–1.753) 0.002
BDI 0.830 (0.764–0.903) <0.001
6MWD, m 0.996 (0.994–0.998) <0.001
SpO2 nadir, % 0.962 (0.944–0.98) <0.001
SGRQ
Symptom 1.019 (1.01–1.029) <0.001
Activity 1.014 (1.006–1.022) 0.001
Impact 1.019 (1.009–1.029) <0.001
Total 1.021 (1.011–1.032) <0.001
a; age, gender adjusted
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Because the SGRQ total score included all domain scores
of the SGRQ and there were high correlations between the
total score and each domain score, we only used the
SGRQ total score in multivariate analysis. Moreover, BDI
was excluded from multivariate analysis because of its high
correlation with MMRC. In multivariate analysis using a
forward selection method, the SGRQ total score was an
independent predictor for mortality (HR, 1.012; 95% CI,
1.001–1.023; P = .029), along with percent predicted FVC
(HR, 0.957; 95% CI, 0.944–0.971; P <.001) (Table 3).
The ROC curve analysis for the 3-year mortality rate
demonstrated that the most accurate and optimal cutoff
value for the SGRQ total score was 30 points (area
under the curve, 71.1%; 95% CI 62.8–79.4%; P < .001)
(Fig. 2). MST was significantly shorter in patients with
SGRQ total scores of over 30 points than in patients
with scores under 30 points (MST, 37.7 vs 54.7 months.
HR, 2.047; 95% CI, 1.329–3.153; P = .001) (Fig. 3).
Discussion
This is the first report to show that health status
assessed using the SGRQ total score is an independent
predictor of mortality in patients with IPF. Moreover,
IPF patients with a SGRQ total score higher than 30
points had a higher mortality rate.
The SGRQ is widely used as an assessment tool for
HRQL and is applied as one of the key endpoints in
clinical trials in patients with IPF [24–29] and COPD
[30–32]. However, the impact of HRQL (assessed using
the SGRQ) on survival rate has not been fully studied
in patients with IPF.
In the univariate analysis in this study, the SGRQ as
well as various dimensional clinical factors previously
reported as prognostic factors were significant predictors
for mortality rate. However, the multivariate analyses
showed that both the SGRQ as a patient-reported out-
come and percent predicted FVC as a physiological indi-
cator had superior capabilities as independent predictors
of mortality than other widely known predictors. Base-
line FVC has been reported to be a robust prognostic
factor [12], and was recently included in a prognostic
model [12]. The present study also shows that baseline
FVC remains an important prognostic factor, and the
SGRQ total score is an equally independent prognostic
meaningful factor. This may be because the SGRQ is
derived from multidimensional viewpoints of disease
severity, and so may capture more comprehensive infor-
mation than individual predictive variables.
However, there has been no study on an appropriate
cut off value for the SGRQ total score in predicting mor-
tality in patients with IPF. We showed that patients with
SGRQ total scores higher than 30 points had a remarkably
higher mortality, with a hazard ratio of 2.047. In contrast
to the present results, SGRQ was not a significant pre-
dictive value for mortality in a previously reported
multivariate analysis [33]. The authors of that study
examined a smaller sample size and made diagnoses
from 2000 to 2005 based on 2000 guidelines that were
different from the 2011 ones with a formal multidiscip-
linary discussion (MDD) used in the present study.
The mean value of the SGRQ total score was reported
by Swigris and colleagues to be around 45 points with
Table 3 Multivariate Cox proportional-hazard analysis
Variables Adjusted HRs (95% CI)a p value
FVC, % predicted 0.957 (0.944–0.971) <0.001
SGRQ total 1.012 (1.001–1.023) 0.029
a; age, gender adjusted
Fig. 2 The ROC curve for SGRQ models in predicting 3-year mortality
Fig. 3 The Kaplan-Meier Curve for SGRQ models
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56.9–73.1% in FVC from a literature review [5], versus
34.5 points with 79.7% in FVC in the present study.
Interestingly, the latest rigorous clinical trial of INPULSIS
showed a SGRQ total score (39.6 points) and FVC (79.6%)
closer to our findings. Considering the grave prognosis
with a score higher than 30 points, these scores should be
explicitly considered in the administration of anti-fibrotic
drugs, even though FVC may be preserved.
Recently the importance of comorbidities in IPF was
reported, however, the relationship between HRQL and
comorbidity in IPF has not been fully examined. The
present study showed that comorbidities, especially dia-
betes and orthopedic disease, were related to total score,
however, they didn’t have predictive value in age and
gender adjusted models.
The present study had some limitations. First, this is a
retrospective, single-centered study, and so there may be
selection bias. Further large prospective studies will be
needed to assess the relationship between the SGRQ
and mortality rate. Next, because we examined mild to
moderate cases, results may differ in a different cohort.
Lastly, all the patients in the present study were Japanese,
and it is unclear whether the findings will apply to people
of different ethnicities.
Conclusion
The SGRQ total score was found to be an independent
prognostic factor in patients with IPF, along with percent
predicted FVC. Total scores higher than 30 points were
associated with a higher mortality rate.
Additional file
Additional file 1: Table S1. Spearman’s correlation coefficients
between SGRQ and baseline physiological measures. Table S2. The
relationship between SGRQ and comorbidities. Table S3. SGRQ domain
as predictors for mortality. (DOCX 29 kb)
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